LDE225 for Patients With PTCH1 or SMO Mutated Tumors

Inclusion Criteria

• •Patient has confirmed diagnosis of a select solid tumor (except medulloblastoma, basal cell carcinoma and pancreatic adenocarcinoma) or hematological malignancy (except CML, ALL and AML).
• •Patient has pre-identified tumor with a PTCH1 or SMO mutation.
• •Patient has received at least one prior treatment for recurrent, metastatic and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission.
• •Patient has progressive and measurable disease as per RECIST 1.1. or other appropriate hematological guidelines.
• •Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1